Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: AdverseEvent Clear all
Completed Phase 2 Interventional

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

NCT06605599
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder
Interventions
ABBV-932, Placebo for ABBV-932
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
32
States / cities
Dothan, Alabama • Anaheim, California • Colton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 6:17 PM EDT
Completed Phase 4 Interventional Results available

The Dual Antiplatelet Therapy Study (DAPT Study)

NCT00977938
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
25,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
178
States / cities
Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 21, 2026, 6:17 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Sorrel 25R Injector - Sorrel Clinical Study Protocol

NCT05221333
View directory record Official record
Conditions
Injection Site, Injection Site Reaction, Injection Site Irritation
Interventions
Sorrel Wearable Injector
Device
Lead sponsor
Eitan Medical
Industry
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 21, 2026, 6:17 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder

NCT07071532
View directory record Official record
Conditions
Bipolar Disorder
Interventions
ABBV-932, Itraconazole
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Los Alamitos, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 6:17 PM EDT
Completed Phase 3 Interventional

Sleep, Fatigue, and Dexamethosone in Children With Leukemia

NCT00075101
View directory record Official record
Conditions
Leukemia
Interventions
Dexamethosone
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
5 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2008 · Synced Oct 21, 2026, 6:17 PM EDT
Recruiting No phase listed Observational

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

NCT06635954
View directory record Official record
Conditions
Cancer, Immunotherapy, PD-1, PD-L1, Immune Checkpoint Therapy
Interventions
Not listed
Lead sponsor
Oxford Biodynamics Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Norwich, Connecticut • Dublin, Georgia • Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 21, 2026, 6:17 PM EDT
Completed No phase listed Observational

Cardiovascular Effects of CART Cell Therapy

NCT04026737
View directory record Official record
Conditions
Leukemia, Lymphoma, Cardiotoxicity, Risk Factor, Cardiovascular, Immunotherapy
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 21, 2026, 6:17 PM EDT
Recruiting Not applicable Interventional

Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer

NCT05984888
View directory record Official record
Conditions
Breast Cancer
Interventions
MIND Diet Intervention Group, General Health Curriculum (GHC) Group
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 21, 2026, 6:17 PM EDT
Recruiting Phase 2 Interventional

Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT07761910
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
Interventions
PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
Diagnostic Test · Device · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 21, 2026, 6:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Drug Exposure and Depot Medroxyprogesterone Acetate (DMPA) in Adolescent Subjects

NCT01461824
View directory record Official record
Conditions
Weight Gain, Disorder of Bone Density and Structure, Unspecified, Uterine Bleeding
Interventions
Depot medroxyprogesterone acetate (DMPA)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 21, 2026, 6:17 PM EDT
Completed No phase listed Observational

Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity

NCT02798679
View directory record Official record
Conditions
Cardiotoxicity
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 21, 2026, 6:17 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis

NCT02319616
View directory record Official record
Conditions
Toxic Epidermal Necrolysis
Interventions
Clobetasol 0.05% ointment, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
7 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2019 · Synced Oct 21, 2026, 6:17 PM EDT
Recruiting Not applicable Interventional

A Study of a Side Effects and Resource Navigation Program for People With Cancer

NCT07646847
View directory record Official record
Conditions
Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer
Interventions
Immunotherapy CARE Program
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 6:17 PM EDT
Completed Phase 1 Interventional

Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

NCT02118987
View directory record Official record
Conditions
Drug Allergy
Interventions
Omalizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 21, 2026, 6:17 PM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

NCT04262336
View directory record Official record
Conditions
Ototoxicity
Interventions
DB-020, Placebo
Drug
Lead sponsor
Decibel Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Miami, Florida • Kansas City, Kansas • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 21, 2026, 6:17 PM EDT
Completed Phase 3 Interventional Results available

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

NCT00400946
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Interventions
asparaginase, cyclophosphamide, cytarabine, dexamethasone, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, mercaptopurine, methotrexate, methylprednisolone, pegaspargase, prednisolone, therapeutic hydrocortisone, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 6:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623
View directory record Official record
Conditions
Non Small Cell Lung Carcinoma, c-MET
Interventions
Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Fullerton, California • Oxnard, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 6:17 PM EDT
Not listed Not applicable Interventional

Improving Geriatric Drug Safety in Underserved Practices

NCT00277173
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Adoption of Crew Resource Management approach
Behavioral
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
65 Years and older
Enrollment
4,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2006 · Synced Oct 21, 2026, 6:17 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06318273
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ABBV-969
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Male only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Duarte, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 21, 2026, 6:17 PM EDT
Terminated Not applicable Interventional Results available

Intrathecal Morphine Compared to Conventional Medical Management for Pain Control and Opioid-related Side Effects

NCT01924182
View directory record Official record
Conditions
Chronic Pain
Interventions
SynchroMed Infusion System and Intrathecal Morphine Sulfate, Conventional Medicine
Device · Other
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Homewood, Alabama • Napa, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 21, 2026, 6:17 PM EDT
Completed Phase 2 Interventional

13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer

NCT00002586
View directory record Official record
Conditions
Drug Toxicity, Lung Cancer
Interventions
13-cis retinoic acid, Tocopherol
Drug · Dietary Supplement
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2005
U.S. locations
4
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 21, 2026, 6:17 PM EDT
Suspended Phase 1Phase 2 Interventional

Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical

NCT06643494
View directory record Official record
Conditions
Prostate Cancer
Interventions
N-111, Placebo
Dietary Supplement · Other
Lead sponsor
Optimal Health Research
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 21, 2026, 6:17 PM EDT
Completed Phase 3 Interventional Results available

Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally

NCT01380197
View directory record Official record
Conditions
Pain, Sickle Cell Disease
Interventions
Morphine, Nubain
Drug
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
6 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 21, 2026, 6:17 PM EDT
Enrolling by invitation No phase listed Observational

Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors

NCT06211413
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Atrial Fibrillation, Hypertension, Cardiotoxicity
Interventions
no intervention
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 6:17 PM EDT